See more : River Eletec Corporation (6666.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cresco Labs Inc. (CRLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cresco Labs Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Urbana Corporation (URB-A.CN) Income Statement Analysis – Financial Results
- Himadri Speciality Chemical Limited (HSCL.BO) Income Statement Analysis – Financial Results
- MAG Silver Corp. (MAG.TO) Income Statement Analysis – Financial Results
- Business Warrior Corporation (BZWR) Income Statement Analysis – Financial Results
- RemeGen Co., Ltd. (9995.HK) Income Statement Analysis – Financial Results
Cresco Labs Inc. (CRLBF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.crescolabs.com
About Cresco Labs Inc.
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was founded in 2013 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 770.89M | 842.68M | 821.68M | 476.25M | 128.53M | 43.25M | 10.31M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 441.00M | 435.67M | 415.34M | 192.31M | 64.45M | 2.84M | 9.16M | 14.57 | 61.11 | 82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 329.89M | 407.01M | 406.35M | 283.94M | 64.08M | 40.42M | 1.15M | 3.16M | -61.11 | -82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 42.79% | 48.30% | 49.45% | 59.62% | 49.86% | 93.45% | 11.17% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 1.99M | 370.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.81M | 54.99M | 40.34M | 160.94M | 77.15M | 29.16M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 439.16K | 300.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.30M | 15.58M | 29.73M | 19.03M | 12.63M | 2.05M | 455.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45K | 8.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.81K | 16.46K |
| SG&A | 259.81M | 350.65M | 317.80M | 179.97M | 89.78M | 31.21M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 440.60K | 308.96K | 673.66K | 442.67K | 1.56M | 437.22K | 244.28K | 130.92K | 45.36K | 31.81K | 16.46K |
| Other Expenses | 151.02M | -572.00K | 753.00K | 48.13M | 8.56M | 27.00K | 663.85 | 9.23K | 9.91K | 9.09K | 53.77K | 70.09K | 227.95K | 253.46K | 22.40K | -303.78K | 1.07K | 21.70K | 766.91 | 1.16K | -119.15K | 127.65K | 209.13K | 319.18K | 231.94K |
| Operating Expenses | 435.36M | 350.08M | 318.56M | 228.10M | 98.34M | 33.82M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Cost & Expenses | 858.71M | 785.75M | 733.89M | 420.41M | 162.79M | 36.65M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Interest Income | 2.42M | 679.00K | 938.00K | 1.41M | 1.58M | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.96K | 18.40K | 0.00 | 1.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 63.24M | 58.52M | 52.15M | 40.91M | 9.46M | 89.00K | 41.60K | 30.81K | 26.49K | 33.62K | 48.18K | 39.92K | 39.75K | 49.55K | 32.63K | 3.78K | 0.00 | 1.10M | 0.00 | 0.00 | 182.35K | 0.00 | 0.00 | 132.58K | 0.69 |
| Depreciation & Amortization | 70.57M | 55.44M | 44.55M | 38.70M | 12.19M | 2.17M | 646.00K | 14.57 | 61.53 | 82.48 | 116.50 | 158.61 | 194.51 | 542.64 | 374.50 | 1.55K | 1.07K | 1.49K | 766.91 | 1.61 | 126.41K | 1.31 | 44.13K | 46.75K | 34.57K |
| EBITDA | -14.62M | -10.24M | -157.04M | 6.75M | -30.09M | 9.66M | -3.48M | -33.61K | 73.43K | -84.07K | -154.56K | -322.46K | 4.52K | -2.23M | -2.88M | -2.03M | -559.24K | -979.09K | -1.56M | -441.25K | -181.08K | -130.92K | -31.58K | -304.24K | -213.84K |
| EBITDA Ratio | -1.90% | 14.65% | 16.18% | 20.65% | -13.77% | 23.84% | -0.42% | -1.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.82M | 65.75M | 87.97M | 58.31M | -34.26M | 4.95M | -44.42K | -33.63K | 65.89K | -51.18K | -154.55K | -310.43K | -379.27K | -388.43K | -473.61K | -595.88K | -674.73K | -1.00M | -1.56M | -441.25K | -307.49K | -130.92K | -103.26K | -350.99K | -248.41K |
| Operating Income Ratio | -11.39% | 7.80% | 10.71% | 12.24% | -26.65% | 11.43% | -0.43% | -1.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -59.08M | -42.61M | -39.38M | -40.71M | -28.95M | -1.29M | 139.77K | 53.05K | 96.42K | -56.92K | 5.59K | 20.51K | 186.63K | -1.89M | -2.44M | -1.72M | 90.18K | -537.39K | 43.16K | 1.16K | -182.35K | 127.65K | 195.35K | -132.58K | -0.69 |
| Income Before Tax | -146.90M | -126.91M | -256.73M | 7.16M | -50.84M | 7.47M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -151.32K | -85.43K | -2.91M | -2.05M | -584.55K | -981.24K | -1.51M | -440.09K | -489.85K | -3.27K | 92.09K | -483.57K | -248.41K |
| Income Before Tax Ratio | -19.06% | -15.06% | -31.24% | 1.50% | -39.55% | 17.26% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 32.95M | 88.94M | 40.11M | 43.72M | 14.46M | 4.37M | -663.85 | 43.59K | -7.98K | 32.64K | 0.00 | 11.03K | -342.40K | 4.03M | 2.47M | -19.39K | -90.18K | 1.10M | -146.31K | -3.00K | 131.48K | -116.13K | -158.23K | 132.58K | 0.69 |
| Net Income | -175.52M | -215.84M | -296.83M | -36.56M | -65.30M | -1.92M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -36.87K | -2.28M | -2.91M | -2.03M | -584.55K | -981.24K | -1.37M | -438.25K | -438.97K | -14.79K | 82.52K | -483.57K | -248.41K |
| Net Income Ratio | -22.77% | -25.61% | -36.13% | -7.68% | -50.81% | -4.43% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.38 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| EPS Diluted | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.37 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| Weighted Avg Shares Out | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.79K | 34.79K | 34.79K | 34.79K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
| Weighted Avg Shares Out (Dil) | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
3 Top Marijuana Stocks To Watch Today For Better Momentum
As 2024 comes to a close, 2025 could be a big year for legal cannabis markets. The better the industry does, the better the odds are at seeing marijuana stocks lower in volatility and rise in momentum. For instance, when...
Top Marijuana Stocks to Watch for Explosive Growth Opportunities
The US cannabis industry continues to show resilience, with steady growth despite recent challenges. The industry is valued at approximately $30 billion and is projected to exceed $50 billion by 2030. Recent pullbacks in marijuana stocks created opportunities for investors,...
Top Marijuana Stocks to Watch as the Cannabis Market Faces Decline
The US cannabis market recently experienced a notable pullback, creating fresh opportunities to watch top marijuana stocks. With a potential shift in federal reform under a Republican-led government, investors are increasingly optimistic about the industry's regulatory future. The US cannabis...
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates
Cresco Labs Inc. (CRLBF) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.04 per share a year ago.
Cresco Labs Inc. (CRLBF) Q3 2024 Earnings Call Transcript
Cresco Labs Inc. (OTCQX:CRLBF) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants TJ Cole - SVP, Corporate Development & Investor Relations Charles Bachtell - Co-Founder & Chief Executive Officer Dennis Olis - Chief Financial Officer...
Cresco Labs Demonstrates Success of Cash Flow Focused Strategy with Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Cresco Labs Underlines the Successful Strategy Focused on Cash Flow with Third Quarter 2024 Financial Results.
3 Marijuana Stocks For Better Gains Today
Over the last several months the US cannabis industry has been on fire. More companies are expanding operations focusing on the future. With federal reform still up in the air state-level regulations are taking precedence. Right now there is a...
These Marijuana Stocks Could Be The Best Investment
With the rapid expansion of the cannabis industry, more people are searching for ways to get involved. From just the inception of legal cannabis to California becoming ground zero for medical marijuana in 1996. This is where the momentum began...
Top Marijuana Stocks to Watch This Week: Leading Picks for Growth
The US cannabis industry has been growing rapidly, with estimates predicting it will reach $50 billion in annual sales by 2025. Recent news surrounding potential federal legalization has caused significant movement in marijuana stocks. Lawmakers continue to discuss the SAFE...
Cresco Labs to Report Third Quarter 2024 Financial Results on November 8, 2024
CHICAGO--(BUSINESS WIRE)--CRESCO LABS TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON NOVEMBER 8, 2024.
Source: https://incomestatements.info
Category: Stock Reports